{"hands_on_practices": [{"introduction": "Effective management of Langerhans cell histiocytosis (LCH) begins not just with diagnosis, but with an accurate assessment of disease extent and severity. This requires applying a standardized risk-stratification system that distinguishes between single-system and multisystem disease, with special attention to the involvement of \"risk organs\" like the liver, spleen, and hematopoietic system. This exercise [@problem_id:5165842] will hone your ability to synthesize diverse clinical, laboratory, and imaging data to correctly classify a patient, a critical step that dictates the entire therapeutic strategy.", "problem": "A $2$-year-old boy presents with a $6$-week history of a pruritic, seborrheic-appearing rash on the scalp and trunk and intermittent limp. Examination reveals scattered erythematous papules with scale and a tender swelling over the right parietal skull. Plain radiographs show two well-circumscribed lytic lesions: one in the right parietal bone and one in the diaphysis of the left femur. There is no clinical hepatosplenomegaly. Laboratory studies show hemoglobin $11.6\\ \\mathrm{g/dL}$, platelets $310\\times 10^{9}/\\mathrm{L}$, white blood cells $7.8\\times 10^{9}/\\mathrm{L}$, aspartate aminotransferase (AST) $82\\ \\mathrm{U/L}$, alanine aminotransferase (ALT) $96\\ \\mathrm{U/L}$, total bilirubin $0.5\\ \\mathrm{mg/dL}$, albumin $4.1\\ \\mathrm{g/dL}$, and international normalized ratio (INR) $1.0$. Abdominal ultrasound demonstrates a normal liver size and echotexture without biliary dilatation and a normal spleen size. Bone marrow aspirate is normocellular without evidence of infiltration. Skin biopsy demonstrates clusters of CD$1\\mathrm{a}^{+}$/langerin$^{+}$ cells with reniform nuclei.\n\nUsing the accepted classification scheme for Langerhans cell histiocytosis (LCH), decide whether this child meets risk-organ criteria and select the most appropriate initial therapeutic approach. Base your reasoning on core definitions: in LCH, organ involvement is classified as single-system versus multisystem disease, and “risk organs” are those whose dysfunction predicts higher mortality (liver, spleen, and hematopoietic system). Risk-organ involvement in the liver is defined by functional impairment (for example, cholestasis with direct hyperbilirubinemia, hypoalbuminemia from synthetic failure, coagulopathy, hepatomegaly with sclerosing cholangitis), in the spleen by clinically significant splenomegaly with hypersplenism, and in the hematopoietic system by cytopenias due to marrow involvement. Mild, isolated aminotransferase elevation without cholestasis or synthetic dysfunction may occur and is not, by itself, sufficient for risk-organ designation.\n\nWhich of the following is the best classification and initial management decision?\n\nA. Multisystem LCH without risk-organ involvement; initiate systemic therapy with prednisone plus vinblastine per protocol, without escalation solely for mild transaminitis.\n\nB. Multisystem LCH with risk-organ involvement on the basis of elevated AST/ALT; intensify upfront therapy by adding mercaptopurine and plan early salvage if no rapid normalization of enzymes.\n\nC. Single-system LCH (bone) with secondary skin irritation; manage with local curettage of bone lesions and topical steroids for the rash without systemic therapy.\n\nD. Central nervous system (CNS)-risk disease due to a skull lesion; begin upfront targeted therapy with a v-raf murine sarcoma viral oncogene homolog B (BRAF) inhibitor to preempt neurodegeneration.\n\nE. Multisystem LCH without risk-organ involvement; however, escalate to cladribine induction because biochemical liver involvement predicts poor response to standard vinblastine and prednisone.", "solution": "The user has provided a clinical vignette and has tasked me with validating the problem statement, classifying the patient's condition according to the provided definitions, and selecting the most appropriate therapeutic approach.\n\n### Problem Validation\n\n**Step 1: Extract Givens**\n\n*   **Patient Profile**: A $2$-year-old boy.\n*   **History**: $6$-week history of a pruritic, seborrheic-appearing rash on the scalp and trunk, and an intermittent limp.\n*   **Physical Findings**: Scattered erythematous papules with scale, a tender swelling over the right parietal skull, and no clinical hepatosplenomegaly.\n*   **Radiological Findings**: Two well-circumscribed lytic lesions located in the right parietal bone and the diaphysis of the left femur.\n*   **Laboratory Data**: Hemoglobin $11.6\\ \\mathrm{g/dL}$, platelets $310\\times 10^{9}/\\mathrm{L}$, white blood cells $7.8\\times 10^{9}/\\mathrm{L}$, AST $82\\ \\mathrm{U/L}$, ALT $96\\ \\mathrm{U/L}$, total bilirubin $0.5\\ \\mathrm{mg/dL}$, albumin $4.1\\ \\mathrm{g/dL}$, INR $1.0$.\n*   **Imaging Data**: Abdominal ultrasound shows normal liver and spleen size, normal liver echotexture, and no biliary dilatation.\n*   **Histopathology/Cytology**: Bone marrow aspirate is normocellular with no infiltration. Skin biopsy confirms diagnosis with CD$1\\mathrm{a}^{+}$/langerin$^{+}$ cells having reniform nuclei.\n*   **Provided Definitions for Langerhans Cell Histiocytosis (LCH)**:\n    *   **System Involvement**: Classified as single-system or multisystem disease.\n    *   **Risk Organs**: Liver, spleen, and hematopoietic system. Dysfunction in these organs is associated with higher mortality.\n    *   **Liver Risk-Organ Involvement Criteria**: Functional impairment such as cholestasis (direct hyperbilirubinemia), hypoalbuminemia, coagulopathy, or hepatomegaly with sclerosing cholangitis.\n    *   **Spleen Risk-Organ Involvement Criteria**: Clinically significant splenomegaly with hypersplenism.\n    *   **Hematopoietic System Risk-Organ Involvement Criteria**: Cytopenias resulting from marrow involvement.\n    *   **Specific Guideline on Liver Enzymes**: Mild, isolated aminotransferase elevation without cholestasis or synthetic dysfunction is explicitly stated as **not sufficient** for risk-organ designation.\n\n**Step 2: Validate Using Extracted Givens**\n\nThe problem statement presents a detailed and self-contained clinical case.\n\n*   **Scientific Grounding**: The case is a classic and realistic representation of Langerhans cell histiocytosis in a young child. The clinical signs (seborrheic rash, bone pain/lesions), diagnostic confirmation (CD$1\\mathrm{a}^{+}$/langerin$^{+}$ cells), and laboratory findings are all consistent with established medical literature on LCH. The definitions and therapeutic concepts provided are in line with current international standards of care and classification schemes (e.g., from the Histiocyte Society). The problem is scientifically sound.\n*   **Well-Posedness**: The problem is well-posed. It provides sufficient data to apply the given classification rules and determine the patient's risk category. The question asks for a specific output (classification and management) that can be logically derived from the premise.\n*   **Objectivity**: The problem is articulated using objective, quantitative, and standard clinical terminology. It is free from subjective or ambiguous language.\n\nThe problem statement does not violate any of the criteria for invalidity. It is a valid, well-structured problem in clinical reasoning.\n\n**Verdict**: The problem is valid. I will proceed to the solution.\n\n### Derivation of Solution\n\n**1. Establish the Diagnosis and System Involvement**\nThe skin biopsy finding of \"clusters of CD$1\\mathrm{a}^{+}$/langerin$^{+}$ cells with reniform nuclei\" is pathognomonic for LCH, confirming the diagnosis.\nThe patient has involvement of at least two distinct organ systems:\n*   **Skin**: Confirmed by the characteristic rash and positive biopsy.\n*   **Bone**: Confirmed by two lytic lesions on plain radiographs (parietal skull and femur).\nAccording to the provided definition, involvement of two or more organ systems constitutes **multisystem LCH**.\n\n**2. Assess for Risk-Organ Involvement**\nThe problem defines risk organs as the liver, spleen, and hematopoietic system. I must evaluate each based on the patient's data and the specific criteria provided.\n\n*   **Hematopoietic System**: The criterion is cytopenia due to marrow involvement.\n    *   Hemoglobin: $11.6\\ \\mathrm{g/dL}$ (normal for a $2$-year-old).\n    *   Platelets: $310\\times 10^{9}/\\mathrm{L}$ (normal).\n    *   White Blood Cells: $7.8\\times 10^{9}/\\mathrm{L}$ (normal).\n    *   Bone Marrow: \"normocellular without evidence of infiltration\".\n    *   **Conclusion**: There are no cytopenias and the bone marrow is not infiltrated. The hematopoietic system is **not** a risk organ in this case.\n\n*   **Spleen**: The criterion is clinically significant splenomegaly with hypersplenism.\n    *   Physical Exam: \"no clinical hepatosplenomegaly\".\n    *   Ultrasound: \"normal spleen size\".\n    *   **Conclusion**: The spleen is of normal size and there is no evidence of hypersplenism (e.g., from the normal blood counts). The spleen is **not** a risk organ.\n\n*   **Liver**: The criterion is functional impairment. The problem explicitly states that mild, isolated aminotransferase elevation is insufficient for this designation.\n    *   AST ($82\\ \\mathrm{U/L}$) and ALT ($96\\ \\mathrm{U/L}$) are mildly elevated.\n    *   However, markers of liver function are normal:\n        *   Cholestasis is absent (Total bilirubin $0.5\\ \\mathrm{mg/dL}$, no biliary dilatation).\n        *   Synthetic function is intact (Albumin $4.1\\ \\mathrm{g/dL}$, INR $1.0$).\n    *   There is no hepatomegaly on exam or ultrasound.\n    *   **Conclusion**: The patient has only mild transaminitis without any evidence of liver dysfunction. Per the problem's explicit rule, the liver is **not** a risk organ.\n\n**3. Final Classification and Therapeutic Strategy**\nThe patient has **multisystem LCH without risk-organ involvement**.\nThe standard of care for this risk group is systemic therapy. Local-only approaches are insufficient for multisystem disease. The established first-line regimen is a combination of a corticosteroid (prednisone) and a vinca alkaloid (vinblastine). Escalation to more intensive therapies (e.g., adding mercaptopurine, using cladribine) is reserved for patients with risk-organ involvement or those who do not respond to initial standard therapy. The presence of a skull lesion is a risk factor for future CNS complications but does not alter the initial systemic therapy away from the standard vinblastine/prednisone protocol; upfront use of BRAF inhibitors as prophylaxis is not standard practice.\n\n### Option-by-Option Analysis\n\n**A. Multisystem LCH without risk-organ involvement; initiate systemic therapy with prednisone plus vinblastine per protocol, without escalation solely for mild transaminitis.**\nThis option presents the correct classification (Multisystem LCH without risk-organ involvement) based on the analysis. The proposed management (systemic prednisone plus vinblastine) is the standard of care for this risk stratum. The statement correctly clarifies that the mild transaminitis is not an indication for escalating therapy. This aligns perfectly with the derived solution.\n**Verdict: Correct.**\n\n**B. Multisystem LCH with risk-organ involvement on the basis of elevated AST/ALT; intensify upfront therapy by adding mercaptopurine and plan early salvage if no rapid normalization of enzymes.**\nThis option incorrectly classifies the patient as having risk-organ involvement. The problem explicitly states that isolated elevation of AST/ALT does not meet the criteria for liver risk-organ involvement. The proposed intensified therapy is therefore inappropriate for this patient's risk classification.\n**Verdict: Incorrect.**\n\n**C. Single-system LCH (bone) with secondary skin irritation; manage with local curettage of bone lesions and topical steroids for the rash without systemic therapy.**\nThis option incorrectly classifies the disease as single-system. The patient has confirmed LCH in two systems (skin and bone), which is, by definition, multisystem disease. The proposed management with only local therapy is inadequate for multisystem LCH.\n**Verdict: Incorrect.**\n\n**D. Central nervous system (CNS)-risk disease due to a skull lesion; begin upfront targeted therapy with a v-raf murine sarcoma viral oncogene homolog B (BRAF) inhibitor to preempt neurodegeneration.**\nWhile a skull lesion does confer a risk for future CNS disease, it does not change the initial risk stratification for therapy. The term \"CNS-risk disease\" is used for treatment considerations, but it does not supersede the fundamental classification. More importantly, the proposed management is not the standard of care. BRAF inhibitors are typically used for refractory/relapsed disease with a confirmed BRAF mutation, not as upfront prophylactic therapy.\n**Verdict: Incorrect.**\n\n**E. Multisystem LCH without risk-organ involvement; however, escalate to cladribine induction because biochemical liver involvement predicts poor response to standard vinblastine and prednisone.**\nThis option correctly identifies the risk classification but proposes an inappropriate management plan. Escalating to a more toxic agent like cladribine as first-line therapy is not standard for this low-risk multisystem group. The justification contradicts the provided rule that \"mild, isolated aminotransferase elevation\" is not sufficient for risk-organ designation and thus should not alter the standard treatment plan.\n**Verdict: Incorrect.**", "answer": "$$\\boxed{A}$$", "id": "5165842"}, {"introduction": "Beyond clinical classification, understanding the molecular underpinnings of LCH is now central to its diagnosis and future therapeutic development. The majority of cases are driven by mutations activating the MAPK pathway, most commonly the $BRAF^{V600E}$ mutation. This practice [@problem_id:4861890] explores the quantitative link between the variant allele frequency ($f_{VAF}$) reported by sequencing and the true fraction of mutant cells, providing a crucial bridge between a key molecular diagnostic report and the underlying disease biology.", "problem": "A clinician is evaluating a patient with Langerhans cell histiocytosis, a clonal myeloid neoplasm in which constitutive activation of the Mitogen-Activated Protein Kinase (MAPK) pathway through the B-Rapidly Accelerated Fibrosarcoma (BRAF) V600E mutation drives extracellular signal-regulated kinase (ERK) phosphorylation in mutant cells. In a bulk tissue specimen, high-depth sequencing reports a BRAF V600E variant allele frequency of $0.25$. Independent histopathologic quantitation estimates the tumor purity (fraction of lesional myeloid cells among all nucleated cells in the specimen) as $0.40$. Assume a diploid genome, heterozygosity of the mutation in the cells that carry it, absence of the mutation in non-lesional cells, and that ERK is fully active in all mutant cells and inactive in all non-mutant cells.\n\nUsing only the core definitions that (i) variant allele frequency is the fraction of sequencing reads carrying the mutant allele among all allelic reads in the bulk mixture and (ii) each diploid cell contributes two alleles, derive from first principles the relationship between the observed variant allele frequency and the fraction of ERK-active cells in the specimen. Then, use the provided values to calculate the predicted fraction of ERK-active cells in the specimen as a decimal. Express your final answer as a decimal fraction. No rounding is required.", "solution": "The problem requires the derivation of a relationship between the variant allele frequency (VAF) of a heterozygous mutation and the fraction of cells in a sample that harbor this mutation, followed by a calculation using provided data. The core of this problem rests on a clear, first-principles definition of VAF in the context of a mixed population of cells.\n\nLet us define the relevant variables as follows:\n- $f_{VAF}$ is the variant allele frequency of the BRAF V600E mutation.\n- $f_{ERK}$ is the fraction of ERK-active cells in the specimen.\n- $f_{M}$ is the fraction of mutant cells (cells carrying the BRAF V600E mutation) among all nucleated cells.\n- $P_{T}$ is the tumor purity, defined as the fraction of lesional myeloid cells among all nucleated cells.\n- $N$ is the total number of nucleated cells in the bulk tissue specimen.\n\nThe problem makes several key statements that establish equivalences between these fractions:\n1.  \"ERK is fully active in all mutant cells and inactive in all non-mutant cells.\" This statement directly links the biological activity (ERK phosphorylation) to the genetic status (presence of the mutation). Therefore, the fraction of ERK-active cells is identical to the fraction of mutant cells:\n    $$f_{ERK} = f_{M}$$\n2.  Langerhans cell histiocytosis is described as a clonal neoplasm driven by the BRAF mutation, and tumor purity, $P_{T}$, is defined as the fraction of lesional cells. In this idealized model, the \"lesional cells\" are precisely the \"mutant cells\". Thus:\n    $$f_{M} = P_{T}$$\nCombining these, the quantity we seek to calculate, $f_{ERK}$, is the same as the fraction of mutant cells, $f_{M}$. Our task is to derive the relationship between $f_{M}$ and $f_{VAF}$.\n\nThe variant allele frequency is defined as the ratio of the number of sequencing reads carrying the mutant allele to the total number of reads covering that specific genomic locus. Assuming unbiased sequencing, this frequency is equivalent to the proportion of mutant alleles in the total pool of alleles from the cells in the sample.\n$$f_{VAF} = \\frac{\\text{Total number of mutant alleles}}{\\text{Total number of alleles}}$$\n\nWe can express the numerator and denominator in terms of $f_{M}$ and $N$.\n- The number of mutant cells is $f_{M} \\times N$.\n- The number of non-mutant (wild-type) cells is $(1 - f_{M}) \\times N$.\n\nThe total number of alleles at this locus in the sample depends on the ploidy. The problem states to assume a diploid genome, meaning each cell contains two alleles for the BRAF gene.\n- Total number of alleles = (Total number of cells) $\\times 2 = 2N$.\n\nThe total number of mutant alleles is determined by the number of mutant cells and their zygosity. The problem specifies that the mutation is heterozygous in the cells that carry it.\n- Each mutant cell contains $1$ mutant allele and $1$ wild-type allele.\n- Each non-mutant cell contains $2$ wild-type alleles and $0$ mutant alleles.\n- Therefore, the total number of mutant alleles in the sample is solely from the mutant cell population:\n  Total number of mutant alleles = (Number of mutant cells) $\\times 1 = (f_{M} \\times N) \\times 1 = f_{M}N$.\n\nNow we substitute these expressions back into the definition of $f_{VAF}$:\n$$f_{VAF} = \\frac{f_{M}N}{2N}$$\nThe total number of cells, $N$, cancels from the numerator and denominator, yielding the direct relationship between the variant allele frequency and the fraction of mutant cells:\n$$f_{VAF} = \\frac{f_{M}}{2}$$\nSince we established that $f_{ERK} = f_{M}$, the relationship between the VAF and the fraction of ERK-active cells is:\n$$f_{ERK} = 2 \\times f_{VAF}$$\nThis equation represents the relationship derived from first principles as requested.\n\nThe final step is to calculate the predicted fraction of ERK-active cells using the provided values. The problem gives the BRAF V600E variant allele frequency as $f_{VAF} = 0.25$. Applying our derived formula:\n$$f_{ERK} = 2 \\times 0.25 = 0.5$$\nTherefore, the predicted fraction of ERK-active cells in the specimen is $0.5$.\n\nIt is important to note that the problem also provides an estimated tumor purity of $P_{T} = 0.40$. Within our idealized model, this would imply $f_{ERK} = f_{M} = P_{T} = 0.40$. This value is inconsistent with the prediction of $f_{ERK} = 0.5$ derived from the VAF. Such discrepancies are common in practice and may arise from factors not included in this simplified model (e.g., aneuploidy, copy number alterations, or inaccuracies in histopathologic estimation). However, the problem specifically instructs to derive the relationship involving VAF and then use it to calculate a *predicted* value. This directs us to use the VAF as the input for our model-based calculation. The predicted fraction of ERK-active cells based on the genetic data is therefore $0.5$.", "answer": "$$\\boxed{0.5}$$", "id": "4861890"}, {"introduction": "Once a treatment strategy is selected, the safe and effective administration of chemotherapy depends on precise, individualized dose calculation. In pediatric oncology, dosing is typically based on body surface area ($BSA$) rather than weight to better approximate metabolic rate and drug distribution. This hands-on problem [@problem_id:5165811] provides essential practice in applying this principle, enabling you to convert a standard per-m$^2$ protocol into a patient-specific dose, a fundamental and non-negotiable skill in clinical practice.", "problem": "A child with newly diagnosed Langerhans cell histiocytosis (LCH) is planned for induction therapy with vinblastine, which in pediatric oncology is dosed proportional to Body Surface Area (BSA) because drug disposition scales more closely with surface area than with body mass. Use the well-tested Body Surface Area (BSA) definition in pediatrics,\n$$\n\\mathrm{BSA}=\\sqrt{\\frac{\\text{height}(\\mathrm{cm})\\times \\text{weight}(\\mathrm{kg})}{3600}},\n$$\nto compute the BSA for a child whose height is $110\\,\\mathrm{cm}$ and whose weight is $20\\,\\mathrm{kg}$. Vinblastine is to be given weekly at $6\\,\\mathrm{mg}/\\mathrm{m}^{2}$. Derive the weekly vinblastine dose from first principles by scaling the per-area dose to the patient’s BSA, and provide the numerical value. Express the final dose in $\\mathrm{mg}$ and round your answer to three significant figures.", "solution": "The problem will first be subjected to a rigorous validation process.\n\n### Step 1: Extract Givens\nThe following data and definitions are explicitly provided in the problem statement:\n-   **Patient Condition**: Newly diagnosed Langerhans cell histiocytosis (LCH).\n-   **Therapeutic Agent**: Vinblastine.\n-   **Dosing Basis**: Proportional to Body Surface Area ($\\mathrm{BSA}$).\n-   **BSA Formula**: `$$ \\mathrm{BSA}=\\sqrt{\\frac{\\text{height}(\\mathrm{cm})\\times \\text{weight}(\\mathrm{kg})}{3600}} $$` where the result is implicitly in units of square meters ($\\mathrm{m}^2$).\n-   **Patient Data**:\n    -   Height: $110\\,\\mathrm{cm}$\n    -   Weight: $20\\,\\mathrm{kg}$\n-   **Dosing Regimen**:\n    -   Frequency: Weekly\n    -   Dose rate: $6\\,\\mathrm{mg}/\\mathrm{m}^{2}$\n-   **Required Output**:\n    -   Derivation of the weekly vinblastine dose.\n    -   Numerical value of the weekly dose, expressed in $\\mathrm{mg}$.\n    -   Rounding: The final numerical answer must be rounded to three significant figures.\n\n### Step 2: Validate Using Extracted Givens\nThe problem is assessed against the required criteria.\n-   **Scientifically Grounded**: The problem is grounded in established pediatric oncology practice. Langerhans cell histiocytosis is a recognized disease, and vinblastine is a standard chemotherapeutic agent used in its treatment. The practice of dosing chemotherapeutics based on Body Surface Area ($\\mathrm{BSA}$) is a widespread and long-standing convention in both pediatric and adult oncology. The provided formula for $\\mathrm{BSA}$ is the Mosteller formula, which is one of the most commonly used empirical formulas for this purpose in clinical settings. The specified dosage of $6\\,\\mathrm{mg}/\\mathrm{m}^{2}$ is a standard dose for vinblastine in LCH induction protocols. It must be noted that the Mosteller formula is empirical; the constant $3600$ is not derived from first principles but is a fitting parameter that rectifies the dimensional inconsistency between the input units ($\\mathrm{cm}$, $\\mathrm{kg}$) and the output unit ($\\mathrm{m}^2$). This is a common feature of nomograms and empirical formulas in medicine and does not invalidate the problem, as its use is explicitly defined and sanctioned by the problem statement as a \"well-tested\" definition.\n-   **Well-Posed**: The problem is well-posed. It provides all necessary quantitative data (height, weight, dose per area) and a clear, unambiguous formula to connect them. The objective is clearly stated: calculate the total weekly dose. A unique solution exists.\n-   **Objective**: The problem is stated in precise, objective language. It presents a quantitative task based on factual clinical parameters and an established formula, devoid of subjective or opinion-based content.\n\nThe problem exhibits none of the disqualifying flaws. It is scientifically sound, well-posed, objective, complete, and verifiable.\n\n### Step 3: Verdict and Action\nThe problem is deemed **valid**. A reasoned solution will be formulated.\n\n### Solution Derivation\nThe fundamental principle for calculating the total drug dose is that the total dose is the product of the prescribed dose per unit of a specific parameter and the patient's measured value for that parameter. In this case, the parameter is Body Surface Area ($\\mathrm{BSA}$).\n\nLet $D$ be the total weekly dose in $\\mathrm{mg}$, $d$ be the dose rate in $\\mathrm{mg}/\\mathrm{m}^{2}$, and $A_{\\mathrm{BSA}}$ be the Body Surface Area in $\\mathrm{m}^{2}$. The relationship is:\n$$\nD = d \\times A_{\\mathrm{BSA}}\n$$\n\nThe solution proceeds in two steps:\n1.  Calculate the patient's $\\mathrm{BSA}$, $A_{\\mathrm{BSA}}$, using the provided Mosteller formula.\n2.  Calculate the total weekly dose, $D$, by multiplying the calculated $\\mathrm{BSA}$ by the given dose rate.\n\n**Step 1: Calculation of Body Surface Area ($A_{\\mathrm{BSA}}$)**\n\nThe formula is given as:\n$$\nA_{\\mathrm{BSA}} = \\sqrt{\\frac{\\text{height}(\\mathrm{cm})\\times \\text{weight}(\\mathrm{kg})}{3600}}\n$$\nWe substitute the given values for height ($H = 110\\,\\mathrm{cm}$) and weight ($W = 20\\,\\mathrm{kg}$):\n$$\nA_{\\mathrm{BSA}} = \\sqrt{\\frac{110 \\times 20}{3600}}\n$$\nPerforming the multiplication in the numerator:\n$$\nA_{\\mathrm{BSA}} = \\sqrt{\\frac{2200}{3600}}\n$$\nSimplify the fraction by dividing the numerator and denominator by $100$:\n$$\nA_{\\mathrm{BSA}} = \\sqrt{\\frac{22}{36}}\n$$\nUsing the property of square roots $\\sqrt{a/b} = \\sqrt{a}/\\sqrt{b}$:\n$$\nA_{\\mathrm{BSA}} = \\frac{\\sqrt{22}}{\\sqrt{36}} = \\frac{\\sqrt{22}}{6}\n$$\nThe unit for this result is $\\mathrm{m}^{2}$, as defined by the empirical formula's convention. So, $A_{\\mathrm{BSA}} = \\frac{\\sqrt{22}}{6}\\,\\mathrm{m}^{2}$.\n\n**Step 2: Calculation of the Weekly Vinblastine Dose ($D$)**\n\nThe dose rate is given as $d = 6\\,\\mathrm{mg}/\\mathrm{m}^{2}$. We use the dosing principle $D = d \\times A_{\\mathrm{BSA}}$:\n$$\nD = \\left( 6\\,\\frac{\\mathrm{mg}}{\\mathrm{m}^{2}} \\right) \\times \\left( \\frac{\\sqrt{22}}{6}\\,\\mathrm{m}^{2} \\right)\n$$\nThe numerical factor of $6$ in the dose rate and the denominator of the $\\mathrm{BSA}$ term cancel out. The units of $\\mathrm{m}^{2}$ also cancel, leaving the final unit as $\\mathrm{mg}$, as required.\n$$\nD = \\sqrt{22}\\,\\mathrm{mg}\n$$\nThis is the exact analytical expression for the weekly dose.\n\n**Final Numerical Answer**\n\nThe problem requires a numerical value rounded to three significant figures. We must compute the numerical value of $\\sqrt{22}$:\n$$\n\\sqrt{22} \\approx 4.6904157598...\n$$\nRounding this value to three significant figures involves keeping the first three digits ($4$, $6$, $9$) and examining the fourth digit ($0$). Since $0  5$, we do not round up the last kept digit.\nTherefore, the weekly dose is approximately $4.69\\,\\mathrm{mg}$.", "answer": "$$\\boxed{4.69}$$", "id": "5165811"}]}